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Abstract
Background: Recently, periostin (POSTN), a gene encoding a protein with similarity to the fasciclin
family and involved in cell survival and angiogenesis, has emerged as a promising marker for tumor
progression in various types of human cancers. There is some controversy regarding both POSTN
expression levels and the nature of periostin-producing cells within tumors. In this study, we used
quantitative RT-PCR to assess periostin gene expression in normal tissues, primary cell cultures,
tumor tissues and tumor cell lines.
Results: Periostin expression levels are highly variable in both normal tissues and tumors and
strong POSTN overexpression is mostly detected in tumors from pancreas and liver. POSTN is not
expressed in blood cancers. In melanoma samples, average periostin expression is not increased in
primary tumors whereas POSTN  overexpression was detected in about 60% of melanoma
metastatic tumors in the liver or lymph nodes. Identification of the cellular source of periostin
production in melanoma metastases -cancer cells or stroma- was assessed by comparing periostin
expression in 23 newly-established melanoma cell lines and matched tumors. In contrast to the
reduction by more than 99% of COL6A3 stromal marker mRNA in all cell lines, significant POSTN
transcription was maintained in some melanoma cell lines, suggesting that both stromal cells and
melanoma cells express periostin. The high level of periostin expression in primary cultures of skin
fibroblasts suggests that fibroblasts may contribute for a large part to periostin production in
melanoma-associated stroma. On the other hand, periostin expression in melanoma cells is
probably acquired during the tumorigenic process as 1) normal melanocytes do not express POSTN
and 2) melanoma cells from distinct metastases of the same patient were associated with very
different levels of periostin expression.
Conclusion: Our comparative analysis suggests that, although periostin overexpression is clearly
detected in some cancers, it is not a general feature of tumors. In melanoma, our study identifies
both stromal and melanoma cells as sources of periostin production and correlates POSTN
expression levels with increased primary tumor thickness and metastatic process development.
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Background
A better understanding of the molecular mechanisms
involved in melanoma and cancer progression in general
is undoubtedly a major challenge in the development of
new diagnostic and therapeutic approaches, underlying
the necessity to identify new molecular targets. During the
past decade, global gene expression profiling studies on
various human cancer types, mainly relying on cDNA
microarray technology, led to the identification of new
candidate genes involved in cancer progression. These
included periostin (POSTN), a gene encoding a secreted
90 kDa protein initially identified in a mouse osteoblastic
library as a putative bone adhesion protein [1]. This pro-
tein shows sequence similarity to fasciclin I, an insect cell
adhesion protein involved in central nervous system
development [2], and human β IgH3, a TGF-β 1-induced
protein promoting adhesion and spreading of dermal
fibroblasts [3]. Binding of periostin to αVβ3 and  αVβ5
integrins has been reported to promote cell adhesion and
spreading and to activate the Akt/PKB signaling pathway
leading to increased cellular survival and angiogenesis [4-
6]. In pancreatic cancer cells, periostin was shown to bind
to α6β4 integrin, thereby promoting phosphorylation of
focal adhesion kinase and PKB through activation of the
PI3 kinase pathway [7].
Over the past seven years, periostin was proposed to be a
novel therapeutic target for cancer [8]. Indeed, POSTN
gene was found to be overexpressed in various human
cancers such as ovary [4,9], colon [6], pancreas [7,10],
thyroid [11], oral squamous cell carcinoma [12,13],
breast [5], lung [14] and neuroblastoma [15] and higher
POSTN expression levels were correlated with increased
tumor aggressiveness and/or poorer survival in NSLC
[14,16], SCLC [17], neuroblastoma [15], colon cancers
[6], thyroid carcinomas [11], oral squamous cell carci-
noma [12] and pancreatic ductal adenocarcinoma [10].
However, other studies reported a down-regulation of
POSTN transcription in bladder [18] and lung [19] cancer.
The functional role of periostin in cancer is also under
debate as both tumor-promoting [5-7,10,20,21] and
tumor-suppressing activities [18,19] have been reported:
on one hand, periostin was reported to increase invasive-
ness of tumor cell lines in vitro [7,12,20] but, on the other
hand, periostin expression reduced invasiveness of blad-
der cancer cells [18] and decreased anchorage-independ-
ent growth of T24 bladder cancer cells and SaOS-2
osteosarcoma cell line [19]. In vivo, two reports demon-
strated that POSTN  overexpression in tumor cell lines
increases metastasis and angiogenesis in nude mice and
reduces stress-induced apoptosis [5,6] while another
report provided evidence that periostin suppresses lung
metastasis of mouse melanoma cell line B16-F10 [18].
Although POSTN overexpression does not seem to be sys-
tematic in human tumors, studies agree on the low level
of periostin expression in most tumor cell lines
[4,7,9,13,18,19,21]. Lower levels of POSTN expression in
tumor cell lines compared to tumor tissues are in agree-
ment with studies showing a production of periostin by
stromal cells -and not cancer cells- in tumors
[10,16,17,22]. However, the nature of periostin-produc-
ing cells in tumors is another matter of controversy as sep-
arate  in situ hybridization experiments suggested that
POSTN mRNA is detected in the cytoplasm of cancer cells
[5,7].
In this study, we relied on quantitative RT-PCR to investi-
gate POSTN expression in a series of human normal tis-
sues and tumors. We next focused on cutaneous
melanoma to quantify periostin transcripts in a total of
113 tumor samples, including primary and metastatic
lesions, and we correlated periostin expression with Bres-
low thickness of melanoma primary tumors. Finally, to
investigate the source of periostin production in
melanoma, we analyzed POSTN transcription level in 23
newly-established melanoma cell lines and matched
tumors and compared the results with the expression level
of  COL6A3, a melanoma-associated stromal marker
encoding the α3 chain of collagen VI.
Results
POSTN expression in normal tissues
We used qRT-PCR to quantify periostin expression in var-
ious normal human tissues. Values were normalized with
the level of β-actin expression (Fig. 1A) and given as
[(cDNA  POSTN/cDNA  ACTB) × 104] (POSTN/ACTB ×
104). POSTN was expressed in a wide range of normal tis-
sues but the expression was negligible in PBLs and spleen.
Expression was also very low in salivary gland and thy-
mus. Tissue samples from skin and breast were character-
ized by high POSTN  expression (average expression of
509 ± 418 and 444 ± 390 respectively) although levels
were fluctuating significantly between independent sam-
ples. Similarly, POSTN expression levels measured in four
independent ovarian tissues spanned over a broad range
(from 0.5 ± 0.02 to 151 ± 17). Conversely, periostin
expression levels in normal pancreas, liver, lymph node,
lung or colon were more homogeneous.
The above data suggest that tissues with low fibroblast
content including PBLs, spleen, pancreas or liver show
reduced POSTN expression compared to fibroblast-rich
tissues like skin or breast. Together with previous observa-
tions that fibroblasts may be the source of periostin
expression in various tumors [10,14,16,17], this suggests
that fibroblast content may modulate POSTN expression
level in normal tissues. To evaluate POSTN expression in
fibroblasts, we extracted RNA from fibroblast primary cul-Molecular Cancer 2007, 6:80 http://www.molecular-cancer.com/content/6/1/80
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Quantitative measurement of POSTN expression in human normal tissues and primary cultures Figure 1
Quantitative measurement of POSTN expression in human normal tissues and primary cultures. POSTN and 
ACTB cDNA levels were measured by qRT-PCR based on Taqman technology. For each sample, measurements were done in 
triplicate. POSTN/ACTB × 104 was calculated as [(cDNA POSTN/cDNA ACTB) × 104]. A. POSTN expression in normal tissues. 
Error bars represent standard deviations (SD). The table below the graph gives the average POSTN/ACTB × 104 ± SD values 
for each sample. B. POSTN expression in primary cultures of human embryonic stem cells at day 5 (HUES), fetal lung fibroblasts 
(IMR90), newborn foreskin fibroblasts (HFF2) and adult skin fibroblasts (LB2924). Error bars represent SD.
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tures derived from either fetal lung (IMR90), newborn
foreskin (HFF2) or adult abdominal skin (LB2924).
POSTN expression levels as high as, respectively, 1547 ±
213, 1391 ± 142 and 1267 ± 57 were measured in these
samples (Fig. 1B). This high level of POSTN expression in
fibroblasts was not a consequence of establishing primary
cultures as embryonic stem cell primary cultures (HUES)
were characterized by very low periostin expression level
(4.2 ± 0.5), further suggesting that periostin expression is
not required at the blastocyst embryonic stage.
POSTN expression in various tumors
To evaluate the extent of periostin expression in tumors,
we measured the amount of POSTN  and  ACTB  cDNA
molecules in hematological malignancies and tumors
from pancreas, testis, liver, bladder, prostate, colon, stom-
ach, ovary, lung, kidney and breast (Fig. 2).
In line with the absence of POSTN expression in normal
PBLs, periostin expression levels were negligible in hema-
tological malignancies including leukemia (0.2 ± 0.2) and
myeloma (1.5 ± 3.6). Overall, our data reveal the huge
variability of POSTN  expression levels in most solid
tumors and normal tissues. Hence, increased periostin
expression was only nearly significant in pancreatic aden-
ocarcinoma (656 ± 819 vs 9.1 ± 6.9 for normal pancreas,
P = 0.06). In liver cancer, average POSTN expression was
also increased (902 ± 1308, n = 6) compared to normal
tissue samples (14 ± 11, n = 5) (P = 0.16). In ovarian
tumors,  POSTN  expression levels were about 15-fold
higher than the average level measured in a total of seven
(three separate ovaries and one pool of four) normal tis-
sues (759 ± 708 vs 52 ± 66) (P = 0.14). For lung cancer, we
measured a significant 5-fold increase of POSTN expres-
sion in NSCLC tumors (272 ± 177 vs 55 ± 49 for normal
lung, P = 0.002).
Comparison of POSTN expression in normal tissues and tumors Figure 2
Comparison of POSTN expression in normal tissues and tumors. POSTN and ACTB cDNA levels were measured in 
triplicate in various normal tissues and tumors as described in Fig. 1 legend. Normal tissue samples correspond to samples 
from Fig. 1. POSTN/ACTB × 104 values are given as Mean ± SD in normal tissues (grey bars) and tumors (black bars).
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POSTN expression in primary and metastatic melanoma 
lesions
Next, we investigated POSTN expression in 113 human
cutaneous melanoma samples, including 46 primary
lesions and 67 metastases. Periostin expression in
melanoma was compared to the expression level in nine
normal skin or benign nevus tissues (Fig. 3A). The average
POSTN expression levels amounted to 500 ± 369 in nor-
mal tissues, 489 ± 961 in primary tumors and 1081 ±
1878 in metastases. Although periostin expression levels
were variable in melanoma tumors (Fig. 3A and 3B), aver-
age POSTN expression level was significantly higher in
metastases compared to primary lesions (P = 0.03).
Melanoma metastases were characterized by highly varia-
ble POSTN expression levels. Notably, very low expres-
sion levels (<10) were measured in 9% of melanoma
metastases while 15% of them showed very high levels of
POSTN expression (>2000) (Fig. 3B). To further compare
periostin expression in primary tumors and metastases,
we measured the level of POSTN transcripts in metastases
and matched primary tumors from 11 patients (Fig. 3C).
No correlation was found: POSTN expression was either
reduced (by up to 280-fold), maintained or increased (by
up to 11-fold) in metastases compared to primary
melanoma. Further analysis also revealed that POSTN
transcription levels may vary significantly between dis-
tinct metastases isolated from the same individual
(patients LB2174, LB2201 and LB2077, Fig. 3C). These
variations may be explained by distinct localization of
melanoma metastases as normal skin produces significant
amounts of periostin unlike other organs with very low
endogenous levels of periostin, like lymph nodes or the
liver. Strikingly, our analysis revealed a significant
increase of POSTN  expression in more than 60% of
tumor-invaded lymph nodes (P = 0.003) (Fig. 3D). Con-
versely, tumor-invaded lymph nodes with low POSTN
expression account for the low levels (<100) measured in
a subset of melanoma metastases. Similar observations
were made with hepatic melanoma metastases (Fig. 3D).
Hence, these data demonstrate the POSTN overexpression
in about 60% of melanoma metastases in the liver or
lymph nodes. Periostin overexpression in (sub)cutaneous
melanoma metastases is more difficult to assess as POSTN
transcripts are already abundant in normal skin (Fig. 3D).
POSTN  overexpression in metastatic tumors was con-
firmed by an analysis of 19 hepatic metastases from
intraocular melanoma (Fig. 3E) (P = 0.002).
Earlier reports suggested that periostin expression level
was correlated with tumor aggressiveness and/or poorer
survival in NSCLC [14,16], SCLC [17], neuroblastoma
[15], colon cancers [6], thyroid carcinomas [11], oral
squamous cell carcinoma [12] and pancreatic cancer [10].
Here, we relied on a revised version of Breslow classifica-
tion based on primary tumor thickness [23] to correlate
periostin expression with prognosis of melanoma (Fig. 4).
Quantitative measurement of POSTN expression was per-
formed on a total of 35 primary melanoma lesions.
POSTN expression levels >300 were measured in only 9%
of tumors with Breslow thickness ≤ 4 mm but were
detected in 58% of tumors with Breslow thickness >4 mm.
These data suggest that, in melanoma, increased tumor
thickness may be correlated with increased periostin
expression although tumoral cell content of samples is
difficult to estimate and may vary with tumor thickness.
POSTN expression in melanoma cell lines
To gain more insight into the nature of periostin-produc-
ing cells in metastatic lesions, we measured POSTN
expression levels in newly established melanoma cell
lines and matched tumors. One major difference between
melanoma tumor and cell line cDNA samples is the pres-
ence of stromal cell cDNA in tumors whereas cell lines
derive from malignant cells exclusively.
We measured the level of POSTN  transcripts in 23
melanoma cell lines and matched tumors (Fig. 5A). These
melanoma lines were established in our laboratory and
were subjected to no more than 4 to 11 passages before
POSTN  expression analysis. Overall, POSTN  transcript
abundance was decreased in most cell lines compared to
tumors and expression levels were extremely low (from
0.06 ± 0.01 to 3.4 ± 0.3) in 11 cell lines. However, six cell
lines, LB2077-1, LB2077-4, LB2730-1, LB2174-3, CP50-
1B and LB2800, were characterized by higher periostin
expression (between 149 ± 21 and 3941 ± 362) and, as
expected for a secreted protein, periostin was detected in
the conditioned medium (Fig. 5D). Interestingly, inde-
pendent cell lines derived from distinct metastases of the
same patient were associated with very different levels of
periostin expression (LB2077 and LB2174 patients, Fig.
5A and 5B). Notably, POSTN expression level was <1 in
LB2077-2 cell line derived from a breast metastasis
whereas periostin was expressed at very high level in
LB2077-1 (3941 ± 362) and LB2077-4 (680 ± 73) cell
lines derived from metastases located, respectively, in
scalp sub-cutaneous tissues and heart of the same patient.
Data also suggest that high level of periostin expression in
metastatic tumoral cells is not time-dependent as variable
expression levels were observed during the tumor resec-
tion history of melanoma patients LB2174 and LB2077
(Fig. 5B).
To follow the disappearance of stromal fibroblasts upon
establishment of melanoma cell lines from tumor sam-
ples, we searched for a genetic marker of fibroblasts in
melanoma. cDNA microarray analysis of a series of paired
melanoma tumor and tumor-derived cell line samples
revealed that a set of stromal genes, including the geneMolecular Cancer 2007, 6:80 http://www.molecular-cancer.com/content/6/1/80
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Quantitative analysis of POSTN expression in melanoma Figure 3
Quantitative analysis of POSTN expression in melanoma. A. POSTN and ACTB cDNA levels were measured in triplicate 
in normal skin (n = 6), benign nevi (n = 3) and melanoma primary tumors (n = 46) or metastases (n = 67) as described in Fig. 1 
legend. Error bars represent SD. B. Data from panel A for normal tissues (N), primary tumors (P) and metastases (M) were 
classified into six ranges of POSTN/ACTB × 104 values. C. Comparison of POSTN/ACTB × 104 values between metastases and 
matched primary tumors from 11 patients or between distinct metastases from the same individual (patients LB2174, LB2201 
and LB2077, with indication of tumor resection dates as MM.YY). Error bars represent SD. D. Metastatic tumors (Meta) were 
classified according to their localization (lymph node, liver or (sub)-cutaneous) and POSTN expression levels were compared to 
levels in tissue samples from normal organs (N). E. POSTN/ACTB × 104 values were measured in hepatic metastatic lesions 
from intraocular melanoma (Meta) and normal liver.
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encoding the α3 chain of collagen VI, COL6A3, were sys-
tematically and significantly down-regulated in all cell
lines (data not shown). COL6A3 encodes a fibrillar pro-
tein of the extracellular matrix believed to be involved in
cell anchoring and signaling through interactions with
integrins [24] and induced by TGF-β1 in dermal fibrob-
lasts [25], suggesting that COL6A3  is a good genetic
marker for melanoma-associated stromal fibroblasts.
Hence, we compared COL6A3  expression levels in 12
melanoma cell lines and matched tumors by qRT-PCR
(Fig. 5C). In agreement with microarray data, COL6A3
expression was drastically reduced in all cell lines tested
compared to matched tumors with cell line/tumor ratio of
COL6A3 cDNA ranging from 0.03 to 1.5% (Fig. 5C). By
comparison, cell line/tumor ratio of POSTN expression
was smaller than 1% in only six cases; the ratio was com-
prised between 5 and 8% in three cases and higher than
25% in LB2077-1, LB2077-4 and LB2730-1.
All together, these data suggest that, in about half of the
melanoma samples tested, POSTN expression is restricted
to stromal cells while, in the other half, cancer cells are
another source of periostinproduction. The detection of
POSTN expression in a fraction of melanoma cell lines
suggests either that normal melanocytes express periostin
and that the expression is maintained in some melanoma
cells or that normal melanocytes do not express periostin
but may acquire the ability to express the gene during the
tumorigenic process. To address that issue, we quantified
periostin expression in normal human melanocytes.
Unlike the expression profile detected in skin fibroblasts,
POSTN expression was not detected in melanocytes and
COL6A3 expression was very low (Fig. 6). Therefore, our
data suggest that, in metastatic melanoma tumors, perios-
tin expression can be induced in melanoma cells.
POSTN expression in other cancer cell lines
Finally, to compare the periostin expression levels in
other cancer cell lines with the values obtained in
melanoma, we selected a series of 19 cell lines derived
from tumors of various cancer types (Table 1). POSTN
expression levels <5 were detected in 16/19 cancer cell
lines whereas strong expression was detected in Hs578T
breast cancer cell line and LB831 bladder carcinoma cell
line. Intermediate expression level of 45 ± 4 was measured
in A172 glioblastoma cell line. Hence, these data suggest
that expression of periostin by cancer cells is not restricted
to melanoma cells but may also occur in other cancer
types.
Discussion
The discrepancy between different studies regarding the
expression level of POSTN  in normal tissues and the
recent observation that transcription of the gene is up-reg-
ulated in various tumors [8] prompted us to set up a quan-
titative RT-PCR assay to measure POSTN mRNA in human
normal tissues and tumors.
In normal tissues, previous Northen blot experiments
demonstrated that periostin is not expressed in PBLs,
highly expressed in fetal tissues or serum but studies disa-
greed on the extent of POSTN expression in a series of
other tissues [4,19,21]. Our data confirm the absence of
POSTN transcription in both PBLs and spleen, in agree-
ment with previous observations [4,19]. Salivary gland,
thymus and embryonic stem cells were also characterized
by very low expression levels. The highest POSTN cDNA
Correlation between POSTN expression and Breslow thick- ness of melanoma Figure 4
Correlation between POSTN expression and Breslow 
thickness of melanoma. POSTN and ACTB cDNA levels 
were measured in triplicate in primary tumors of melanoma 
with Breslow thickness <1.0 mm (n = 9), 1.01<>2.0 mm (n = 
8), 2.01<>4.0 mm (n = 6) and >4.0 mm (n = 12) as described 
in Fig. 1 legend.
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Comparison of POSTN expression in melanoma tumors and cell lines Figure 5
Comparison of POSTN expression in melanoma tumors and cell lines. A. A total of 23 melanoma cell lines (black 
bars) and matched metastatic tumors (grey bars) were assessed for POSTN and ACTB expression in triplicate as described in 
Fig. 1 legend. All melanoma cell lines were established in our laboratory and subjected to no more than 4 to 11 passages before 
RNA extraction. Metastases were isolated from tumor-invaded lymph nodes (LB2201-2, LB2730-1, LB2165-1, LB2117-3, 
LB2667-1a, LB2800, LB1448-2, LB2870, EB81-2), skin (DDHK0062, KUL81-2), sub-cutaneous tissues (EB124, CP50-1b, 
LB2174-1, LB2174-3, LB2077-1, LB2821, LB2181-2, LB2763-1, LB2259-1, LB2307-2, VUB105) or heart (LB2077-4). Error bars 
represent SD. B. POSTN expression level was measured in independent melanoma cell lines derived from distinct metastasis of 
patients LB2174, LB2730 and LB2077. Date of cell line establishment (MM.YY) is indicated above the bars. C. POSTN and 
COL6A3 cDNA levels were measured by qRT-PCR in 12 melanoma cell lines and matched tumors. Values are given as (expres-
sion in cell line/expression in tumor) × 100%. D. Periostin protein was analyzed in conditioned medium from LB2077-1 and 
LB2730-1 periostin-producing melanoma cell lines and from LB2181-2 and LB2667-1a melanoma cell lines, which do not 
express POSTN, as negative controls.
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levels were measured in colon, small intestine, breast and
skin. However, in the three latter organs, as well as in kid-
ney and ovaries, expression levels were highly fluctuating
between tissue samples, providing a possible explanation
for the discrepancies between previous studies. The diver-
sity in cell type content among samples may possibly
account for this variability. In that respect, skin samples
contain different cell types including fibroblasts, keratino-
cytes and melanocytes for which we have measured
POSTN expression levels of, respectively, about 1500, 50
(data not shown) and 0.
In tumors, leukemia and myeloma showed negligible lev-
els of periostin expression whereas POSTN  transcripts
were detected in all solid tumors. We detected a 72-fold
increase of POSTN transcription in pancreatic adenocarci-
noma compared to normal tissues (P = 0.06), in line with
previous studies reporting a 42- to more than 100-fold
increase of POSTN  mRNA level in pancreatic tumors
[7,10]. In liver and ovarian tumors, average expression
levels were increased by 65- and 15-fold respectively. The
only evidences for increased periostin expression in liver
cancer reported so far come from immunohistochemical
analysis of tumor tissues [7]. In ovarian tumors, tumor-
derived epithelial cells and ascites, previous semi-quanti-
tative studies reported elevated levels of periostin mRNA
and protein [4,9]. Previous studies reported POSTN up-
regulation in about half of the NSCLC tumors [14] and a
slight increase in periostin serum levels from NSCLC
patients [16]. Higher periostin serum levels were also cor-
related with increasing T- or N-stage in SCLC patients [17]
but, on the other hand, in situ mRNA hybridization sug-
gested a down-regulation of POSTN gene transcription in
SCLC tumors [19]. Our data suggest that POSTN tran-
scription is increased by 5-fold in NSCLC tumors. No sig-
nificant difference was measured for SCLC and NET
tumors although more samples should be analyzed. Anal-
ysis of six colorectal tumors and three normal colon sam-
ples revealed only a 2-fold increase in POSTN expression
(P = 0.16). The modest increase in POSTN transcription
that we measured in colorectal tumor samples does not
match previous data from a semi-quantitative study
reporting considerable periostin overexpression in 25/29
pairs of matched normal colon tissue and colon tumor
samples [6]. The reason for this is unclear but may be
related to the fact that Bao et al. mainly focused on colon
cancers with hepatic metastases. In breast and kidney
tumors, the difference in periostin expression was not sig-
nificant due to the highly variable POSTN expression lev-
els measured in both normal and tumoral samples. The
absence of significant increase in POSTN expression in
breast tumors contrasts with the conclusions from a previ-
ous study in which expression in tumors was compared to
the low level of POSTN mRNA in primary mammary epi-
thelial cultures as reference for normal breast tissue [5].
Overall, for most tumor types tested in this study, our data
revealed highly variable POSTN expression levels in both
tumors and normal tissues, suggesting that larger num-
bers of samples should be tested to address periostin
expression in tumors more significantly.
In normal skin, melanocytes do not express POSTN but
fibroblasts express the gene at high level. Investigation of
46 primary cutaneous melanoma lesions did not reveal
any significant difference in average POSTN expression
compared to normal tissues although we found that, in
primary melanoma, thicker tumors (> 4 mm) may be cor-
related with increased periostin expression (P  = 0.07).
However, melanoma cell content of tumor samples is dif-
ficult to estimate and may vary with tumor thickness,
leading to possible distortion of the data. In metastatic
melanoma lesions, POSTN expression ranged from very
low to very high levels compared to normal skin. Classifi-
cation of melanoma metastases showed that very low
POSTN expression levels are found in metastases located
in organs with low endogenous periostin expression, like
the liver or lymph nodes. In these organs, low POSTN
expression levels are expected if melanoma cells do not
Quantitative measurement of POSTN and COL6A3 expression  in primary cultures of skin fibroblastes and melanocytes Figure 6
Quantitative measurement of POSTN and COL6A3 
expression in primary cultures of skin fibroblastes 
and melanocytes. POSTN, COL6A3 and ACTB cDNA levels 
were measured in triplicate in primary cultures of skin 
fibroblasts (LB2924) and melanocytes (NHEM and LB656). 
COL6A3/ACTB × 104 was calculated as [(cDNA COL6A3/
cDNA ACTB) × 104]. Error bars represent SD.
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produce periostin. Conversely, periostin levels should be
high if melanoma metastases overexpress POSTN either
through acquisition of POSTN expression by melanoma
cells or to increased periostin expression in tumor-associ-
ated stromal cells. In that respect, about 60% of
melanoma metastatic tumors in the liver or lymph nodes
showed a clear POSTN overexpression compared to nor-
mal organs.
The nature of periostin-producing cells in tumors is still
under debate as separate studies reported a production of
periostin by stromal cells [10,16,17,22] whereas other
experiments suggested that POSTN mRNA is detected in
cancer cells [5,7]. To investigate the nature of periostin-
producing cells in melanoma, periostin expression was
measured in newly established melanoma cell lines and
matched tumors. In cell lines, expression of COL6A3 stro-
mal cell marker was reduced to less than 1% of the value
measured in matched tumors whereas periostin was
expressed (at either low or high level) in about half of the
melanoma cell lines. Given that normal melanocytes do
not express periostin, this study suggests that melanoma
cells sometimes acquire the ability to express the gene dur-
ing tumorigenesis. Our data also indicate that cell lines
isolated from distinct metastases of the same patient may
be characterized by either negligible or high POSTN
expression, suggesting that periostin expression is
acquired by melanocytes during the metastatic process.
Previous studies reported low POSTN expression in most
tumor-derived cell lines, whatever their origin
[4,7,9,13,18,19,21] but most cancer cell lines tested had
been established a long time before and subjected to
extensive culture, making it difficult to establish whether
the decreased expression in cancer cell lines was reflecting
a loss of stromal-associated POSTN  expression as sug-
gested by some authors [10,16,17,22] or artifacts due to
prolonged cell culture. The induction of periostin expres-
sion in melanoma cells may be a consequence of muta-
genic events occuring during the tumorigenic processes or
may be the result of interactions with stromal compo-
nents previously reported to influence development and
progression of carcinomas [26]. In that respect, earlier
experiments showed an induction of POSTN expression
in tumors recovered from nude mice injected with perios-
tin-negative transformed cell lines [21] (although one
cannot rule out the possibility that stromal cells them-
selves may be the source of periostin expression in these
tumors). On the other hand, our data indicate that stro-
mal cells are an important source of periostin production
in melanoma tumors. In some instances, periostin expres-
sion levels were higher than 3000 in the tumor but negli-
gible in matching cell lines, suggesting that periostin
expression may be very high in tumor-associated stromal
cells. In line with this, a significant increase in periostin
expression was measured in fibroblast-like stellate cells
from pancreatic ductal adenocarcinoma tumors, a cancer
characterized by excessive desmoplasia [10]. Stromal cells
have a prominent role in cancer progression and cancer-
associated fibroblasts are believed to play a crucial role by
producing growth factors, chemokines and extracellular
matrix components that promote tumor angiogenesis
[27].
The increased expression of periostin in melanoma meta-
static lesions that we identified in this study is in agree-
ment with in vivo studies revealing that periostin
overexpression promotes metastatic growth of cancer cells
[5,6,20,28]. Hence, this work suggests that, in melanoma,
periostin overexpression may also be involved in the proc-
ess of metastasis. In line with this, two previous studies
identified an up-regulation of integrin αV (ITGAV), one of
the subunits of periostin receptor, as a predictive marker
for melanoma metastasis in primary tumors [27,29,30].
Conclusion
Periostin was reported to promote cell survival and angio-
genesis in tumors. Although cancer-associated POSTN
overexpression is well documented for some tumor types,
it is still uncertain for other ones. To date, no quantitative
comparison of periostin expression in a large panel of
normal and tumor tissues was available. In this study, we
detected considerable variability of POSTN transcript lev-
els among samples from the same tissue type, especially
for tissues with variable stroma content. Overall, our
results support previously reported increase of periostin
expression in tumors from pancreas, liver and NSCLC but
suggest that POSTN overexpression is not a general feature
of tumors. In melanoma, POSTN transcription was not
increased in primary lesions compared to normal skin but
was correlated with Breslow thickness. On the other hand,
Table 2: Primers and probes used in qRT-PCR
Gene Primers Probe (6-FAM/TAMRA) Ref.
POSTN 5'-TGCCCAGCAGTTTTGCCCAT
5'-CGTTGCTCTCCAAACCTCTA
5'-TCCCACGATGCCCAGAGTGCCA This study
ACTB 5'-GGCATCGTGATGGACTCCG
5'-GCTGGAAGGTGGACAGCGA
5'-TCAAGATCATTGCTCCTCCTGAGCGC [32]
COL6A3 5'-GAAGACCGGCAGCTCATCAA
5'-CGATGTTGCAGATGTCCAAGCA
5'-CACAGCAGTGGGGCATGCGCTT This studyMolecular Cancer 2007, 6:80 http://www.molecular-cancer.com/content/6/1/80
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about 60% of melanoma metastases from lymph nodes or
the liver overexpress POSTN. Analysis of newly-estab-
lished melanoma cell lines and matched metastases
revealed that, although stromal cells -presumably fibrob-
lasts- are mostly responsible for periostin production in
melanoma metastases, melanoma cells sometimes
acquire the ability to express POSTN at high level. This
acquisition is associated with the metastatic process as dis-
tinct metastases from the same patient were associated
with very different POSTN expression levels. Hence, this
work reconciles previously published studies reporting
conflicting data about the nature of periostin-producing
cells in tumors (stromal or cancer cells) and identifies
POSTN as a marker of metastasis in melanoma.
Methods
Chemicals
Minimum Essential Medium (MEM), Iscove's Modified
Dulbecco's Medium (IMDM), Dulbecco's Modified Eagle
Medium (DMEM), trypsin-EDTA and essential amino
acids were purchased from GIBCO (Invitrogen, Merel-
beke, Belgium); fetal calf serum was from HyClone (Per-
bio Science, Aalst, Belgium); TriPure reagent from Roche
Applied Science Diagnostics (Mannheim, Germany) and
all other reagents were from Sigma Aldrich (Bornem, Bel-
gium).
Primary cultures, normal tissues, tumors and cell lines
IMR90 fetal lung fibroblasts were kindly provided by M.
Ricchetti (Institut Pasteur, Paris, France); HFF-2 newborn
foreskin fibroblasts were purchased from ATCC (Rock-
ville, MD); LB2924 fibroblasts were isolated from adult
abdominal skin in our laboratory and normal human epi-
dermal melanocytes NHEM derived from foreskin were
purchased from PromoCell GmbH (Heidelberg, Ger-
many). Normal tissue and tumor samples were obtained
from patients undergoing surgery or tumor resection
between 1991 and 2006. Experimental procedures involv-
ing the use of biological material were approved by our
Institutional Review Board. All patients gave informed
consent. In general, tumor biopsies were obtained as part
of screening procedures for participation in clinical
immunotherapy trials. The informed consent mentioned
that part of the tumor samples could be used for research
purposes. In a few cases, anterior to 2002, oral informed
consent was obtained. Surgical specimens were immedi-
ately frozen in liquid nitrogen and stored at -80°C until
RNA extraction. Cell lines derived from melanoma, rhab-
domyosarcoma, NSCLC, SCLC, renal cell carcinoma,
bladder carcinoma and larynx epidermoid carcinoma
were derived from patient specimens in our laboratory.
HeLa, PA-1, A172, A375, Hs578T, MCF-7 and Capan-1
cell lines were purchased from ATCC. Cell lines derived
from osteosarcoma (U2OS), hepatocarcinoma (Huh-7),
stomach tumor (MZGC3) and pancreatic carcinoma
Table 1: Periostin expression in various cancer cell lines
Cell line Origin POSTN/ACTB1
U2OS Osteosarcoma 3.5 ± 1.7
LB96 Ewing sarcoma 0
LB23-1 Rhabdomyosarcoma 0.1 ± 0.1
Hela Cervical cancer 3.0 ± 0.4
PA-1 Ovarian teratocarcinoma 1.4 ± 0.1
LB37-1 NSCLC 2.8 ± 0.6
LB85 SCLC 3.4 ± 0.2
LB92 SCLC 0.6 ± 0.2
LB1047 Renal cell carcinoma 0.8 ± 0.2
BB64 Renal cell carcinoma 0.08 ± 0.01
LB108 Colorectal cancer 0
MCF7 Breast cancer 0
Hs578T Breast cancer 3693 ± 86
Panc-1 Pancreatic carcinoma 0
Capan-1 Pancreatic carcinoma 0
Huh-7 Hepatocarcinoma 0.3 ± 0.07
LB831 Bladder carcinoma 1748 ± 74
MZGC3 Stomach cancer 0
A172 Glioblastoma 45 ± 4
MZ2 Melanoma 2.3 ± 0.7
LB39 Melanoma 0.5 ± 0.03
LB2586-7 Melanoma 3.4 ± 0.3
LB2201-3 Melanoma 4.2 ± 0.4
A375 Melanoma 4.7 ± 1.2
1 (cDNA POSTN/cDNA ACTB) × 104Molecular Cancer 2007, 6:80 http://www.molecular-cancer.com/content/6/1/80
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(Panc-1) were kindly provided by, respectively, F. Fuks
(Université Libre de Bruxelles, Brussels, Belgium), A.H.
Patel (University of Oxford, Oxford, UK), P. Coulie (Uni-
versité Catholique de Louvain, Brussels, Belgium) and C.
Hill (Cancer Research UK, London, UK). Fibroblasts were
maintained as a monolayer in MEM media supplemented
with 1% essential amino acids at 37°C in a humidified
atmosphere saturated with 5% CO2. All cancer cell lines
were grown at 37°C in a humidified atmosphere saturated
with 8% CO2  in IMDM except for U2OS and HeLa
(DMEM) and MZ2 and LB23-1 (DMEM/Hepes/glucose)
cell lines. All media were supplemented with 10% fetal
calf serum, 100 U/ml penicillin and 100 μg/ml streptomy-
cin.
RNA extraction and reverse transcription
Total cellular RNA was extracted with TriPure reagent or
by the guanidine-iosthiocyanate/cesium-chloride proce-
dure [31]. RNA samples from 18 normal human tissues
were purchased from either Clontech (Mountain View,
CA) or AMBION (Austin, TX). RNA from LB656 melano-
cytes was kindly provided by L. Old (Ludwig Institute for
Cancer Research, New-York). cDNA synthesis from 2 μg of
total RNA was accomplished by extension with dT18 in the
presence of 200 U M-MLV reverse transcriptase (Invitro-
gen, Merelbeke, Belgium) for 1 h at 42°C in a final vol-
ume of 20 μl. Reaction volume was then adjusted to 100
μl with water. cDNA from HUES human embryonic stem
cells at day 5, synthesized as described above, was a kind
gift of A. Loriot and C. de Smet (Ludwig Institute for Can-
cer Research, Brussels).
Real-time quantitative PCR
Expression levels of β-actin (ACTB) [32], POSTN  and
COL6A3 were measured by qRT-PCR based on TaqMan
technology using the ABI PRISM 7700 Sequence Detec-
tion System (Applied Biosystems, Foster City, CA). Prim-
ers, probes and qPCR Core Kit reagent were purchased
from Eurogentec (Seraing, Belgium). Sequences of prim-
ers and probes are described in Table 2. POSTN primers
were chosen in exon 3 and 5 respectively, allowing the
amplification of all nine POSTN splicing variants. Reac-
tions were done in a final volume of 25 μl with 200 nM
primers, 100 nM probe, 200 μM dNTPs, 5 mM MgCl2,
0.625 U Hot Gold Star polymerase and 2.5 μl cDNA in 1×
buffer. Annealing temperature was of 60°C for POSTN
and COL6A3 and of 62°C for ACTB [32]. Amplicon sizes
were of 186 bp (POSTN), 142 bp (COL6A3) and 613 bp
(ACTB). Standard curve equations were established by
serial dilutions of PCR-amplified cDNA fragments of
POSTN  (602 bp) and COL6A3  (304 bp). cDNA copy
numbers were calculated using the following equations:
log(cDNAACTB) = (Ct-38.5)/3.7; log(cDNAPOSTN) = (Ct-
36.9)/3.35 and log(cDNACOL6A3) = (Ct-37.2)/3.4.
Immunoblotting analysis
To detect secreted periostin in the supernatants, LB2077-
1, LB2730-1 melanoma cells were grown in IMDM
medium until 90–100% confluency and thereafter kept in
serum-free IMDM for 48 hours. LB2181-2 and LB2667-1a
cell lines were used as negative controls. Four ml-superna-
tants from 400 000 cells were collected after 72 hours and
concentrated 10 times using the Microsep centrifugal
devices 10 K (Pall Life Sciences, Ann Arbor, MI). Equal
volumes of concentrated supernatants were subjected to
7% SDS-PAGE and electroblotted onto a PVDF mem-
brane (Millipore). The membrane was incubated succes-
sively with rabbit polyclonal antibody (ab14041, Abcam,
Cambridge, UK) specific for periostin and then horserad-
ish peroxidase-conjugated anti-rabbit IgG (Stressgen, Ann
Arbor, MI). Protein bands were visualized using the Lumi-
nol Reagent (Santa Cruz Biotechnology).
Statistical analysis
Student t-test was applied to compare POSTN expression
in different sample series.
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